MTOR and breast carcinoma: Interestingly, a phase 2 clinical trial is being conducted using hydroxychloroquine, an autophagy inhibitor, and/or mTOR inhibitors to treat patients with breast cancer who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells (clinical trial identifier NCT03032406) [7].